Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$9.25 - $19.97 $100,029 - $215,955
10,814 New
10,814 $197,000
Q4 2022

Feb 07, 2023

BUY
$7.58 - $11.08 $137,235 - $200,603
18,105 New
18,105 $161,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.86B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.